{"name":"Bioxytran Inc.","slug":"bioxytran-inc","ticker":"","exchange":"","domain":"","description":"Bioxytran Inc. is a biotechnology company focused on developing innovative treatments for critical care conditions. The company's lead candidates include Galactomannan in Phase 3 and Prolectin-M in Phase 2, both targeting significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":191077,"revenueGrowth":-22.5,"grossMargin":45.6,"rdSpend":112337,"netIncome":-2366681,"cash":11092,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Galactomannan","genericName":"Galactomannan","slug":"galactomannan","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Galactomannan","genericName":"Galactomannan","slug":"galactomannan","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"pipeline","source":"The Manila Times","summary":"BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT - The Manila Times","headline":"BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPcG1ES1ZYSVo1aFhUeGlGR0g3azlSdWZWRXpiQ0Q0Qi0wZ25LWDZNWGlBelJoZXBxT1RnNjR3OVFGS1lUdjFzaFFMZjhUTl9QeWZUN25DSDh4MTE0UHg3MjJQbjNhMEVpZXJlWTFyZVR6QlhPOXc4N2NqU01GRWhSNmNYU3ZtTXlZdHh3dmFlUUNwdVhzdDlROG5KYnlZaFl3dFpmZmhTYjVFQ2o0ODdCVGRnM3JDaTNOdk96akhBOWNob293SVJnVXdaZ2ktTFVKT0dYRFJEaVFsZXdhTE9MYUhiSDZ6RlE?oc=5","date":"2026-03-02","type":"trial","source":"ACCESS Newswire","summary":"Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 - ACCESS Newswire","headline":"Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mil","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPM2xhNEMyMlY0M29Ud3VjMlZtTTZzdk8ta3YyXzdUYjVHX2NtbnhTSGhMRkd0WXMyazF0aWVoMVRGMk85SncxbGRKdW82ZDBfLUxfYzh2YzAyQVY0eWRWbTBRR2xPZ083YjZVaGNSa3dMSXFRcnRpeFNmd3BVRm1OSnktc0IzbGZkbnNNaHFhR2lwUFZoUE53Yy04OURfRzh0ZkFUcQ?oc=5","date":"2026-03-02","type":"trial","source":"PharmaTimes","summary":"Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M - PharmaTimes","headline":"Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M","sentiment":"positive"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQS2hJUXMyYzJGWm0tTzZRYkZ6YVRoY3MzbnQ1LTVSdFFuRnNVRXR1NDhreUQtdVBOa3BVNWNTYU9SelZPQjRoZUVSVUFUc1VfQ0ZBSG5hY1E3MHRpbGVxcTRLWVJzdGE5WlhvUUFsamp5aHQ4SUhySmJNdi15czVickZ0Y2xEV2lFbkt5b3FDLWVmakVvb0JTdy1Bc2F4MnplU2JOZXU1cURrTHlNOWlGSTlfcUlsbko1RC1PaEdjdlp5TlNobHpTTXI1RjU2Zl9LVWtpbjE4Yy0zUy1qMElWM1pfZUNRa09sa3c?oc=5","date":"2026-02-24","type":"deal","source":"BioPharma APAC","summary":"Bioxytran Initiates University Of Georgia Collaboration Under 100 Million Dollar Grant To Target H5N1 Bird Flu - BioPharma APAC","headline":"Bioxytran Initiates University Of Georgia Collaboration Under 100 Million Dollar Grant To Target H5N1 Bird Flu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ1h3YVJrMkwxVWxrZnR2cGFwa2x6bXYtNXR0SGN4UnIwYTR2Y1pUUmYwTXQtNEhrYVpOb2xHeGtUemJmS1BFaHh2akJKampMRVViZUZwdS1EU2l4Vmx2ZTNsNGktbkIyVXEzNFN0Yk5XR28xLUlXNVpCZjFMY1RVRi1Udkp6M0NUS21qV3FDbjQ3RTNYRXRSWg?oc=5","date":"2026-02-17","type":"pipeline","source":"Yahoo Finance","summary":"Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement - Yahoo Finance","headline":"Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNUEZhd2UtXzZ0MVZEUTBodkFieEJ1R2J5c2JmZGFobDB0RXJRREVUY0psOGhrX3hEZEdaYWJyZ3haN29NeTBQUU5vMk16UTJrSmFGZTBYWmN6U3lUQ2RrWFlFODZVdEF2aWdobGx4aDFrWVpiMTltTzl3dnl4MjlaSERvZWRseTA4WGg3RlJXRzU5T1VPdmxlTGo0dU1uci1KamhXRw?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Bioxytran (OTCQB: BIXT) inks A-SUQAR supplement distribution pact with Khoury Medical - Stock Titan","headline":"Bioxytran (OTCQB: BIXT) inks A-SUQAR supplement distribution pact with Khoury Medical","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQM3dJdUtoZ3FnbURWbjZLejlHam00bERVWG1EeTBSb3UtTDdEXzQwSFRobXFNRXpyOExnZVNPTFNvbC14S3RnajRoLURzWi0ybGE3ZFI5UWs0OExSdjRmWHBZcFk4NFlHWGpfQWdMTGtSWE1PcU5DUXNpRHlsa0l0MG5ydlM1WDlJbEd4LWJYZw?oc=5","date":"2026-02-11","type":"trial","source":"PharmaTimes","summary":"Bioxytran reports rapid viral clearance in phase 2 trial - PharmaTimes","headline":"Bioxytran reports rapid viral clearance in phase 2 trial","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":191077,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":191077,"period":"2017-12-31"},{"value":246495,"period":"2016-12-31"}],"grossProfit":87098,"grossProfitHistory":[],"rdSpend":112337,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-2366681,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":11092,"cashHistory":[],"totalAssets":138694,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}